Results 111 to 120 of about 50,400 (305)

Disease-modifying therapeutic directions for Lewy-Body dementias [PDF]

, 2015
Qiang Zhang, Young-Cho Kim, Nandakumar S. Narayanan   +2 more
openalex   +1 more source

A Biomarker‐Based Classification of Corticobasal Syndrome

Movement Disorders, EarlyView.
Abstract Background Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau‐predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD).
Carla Palleis, Alexander Maximilian Bernhardt, Endy Weidinger, Urban M. Fietzek, Alexander Jäck, Sabrina Katzdobler, Johannes Gnörich, Theresa Bauer, Nicolai Franzmeier, Robert Perneczky, German Imaging Initiative for Tauopathies (GII4T), Matthias Brendel, Johannes Levin, Günter U. Höglinger   +13 more
wiley   +1 more source

LEWY BODY VARIANT OF ALZHEIMER DISEASE

Zdravniški Vestnik, 2003
Background. Clinicopathological studies indicate that Alzheimer’s disease (AD) is the most common neurodegenerative cause of dementia, the other frequent causes are AD combined with diffuse Lewy bodies and dementia with Lewy bodies (DLB) by itself.
Jera Jeruc, Aleš Kogoj, Marko Pišljar, Mara Popović   +3 more
doaj  

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study

BMC Neurology
Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson’s disease.
Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson   +3 more
doaj   +1 more source

Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD.
Lara M. Lange, Zih‐Hua Fang, Laurel Screven, Ai Huey Tan, Roy N. Alcalay, Rim Amouri, Roberta Bovenzi, Matilda Fenn, Joshua L.I. Frost, Joseph Jankovic, Simona Jasaityte, Zane Jaunmuktane, Beomseok Jeon, Ignacio Juan Keller Sarmiento, Rejko Krüger, Gregor Kuhlenbäumer, Chin‐Hsien Lin, Lukas Pavelka, Maria Teresa Periñan, Samia Ben Sassi, Tommaso Schirinzi, Jung Hwan Shin, Joshua M. Shulman, Yi Wen Tay, Ryan Uitti, Tom Warner, Zbigniew K. Wszolek, Lesley Wu, Ruey‐Meei Wu, Kirsten E. Zeuner, Cornelis Blauwendraat, Andrew Singleton, Niccolò E. Mencacci, Huw R. Morris, Shen‐Yang Lim, Katja Lohmann, Christine Klein, the Global Parkinson's Genetics Program (GP2)   +37 more
wiley   +1 more source

Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

Molecular Neurodegeneration
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
Hiroaki Sekiya, Tomoyasu Matsubara, Michael A. DeTure, Dennis W. Dickson   +3 more
doaj   +1 more source

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang, Robert A. Hauser, Lorraine V. Kalia, Bonnie Hersh, Zdenek Berger, Roy Llorens Arenas, Coro Paisan‐Ruiz, Kyle Fraser, Danna Jennings, Jillian H. Kluss, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, J. Timothy Greenamyre   +12 more
wiley   +1 more source

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta‐Analysis

Movement Disorders, EarlyView.
Abstract Background The activation of the NOD‐, LRR‐ and pyrin domain‐containing protein 3 (NLRP3) inflammasome and associated immune dysregulation is one of the key pathological processes preceding and accompanying α‐synuclein pathology, neuronal damage, and cell death in Parkinson's disease (PD).
Alina‐Măriuca Marinescu, Venissa Machado, Gennaro Pagano, Nicoletta Milani Muelhardt, Thomas Kustermann, Eva Zsuzsanna Mracsko, Kathrin Brockmann, Nima Shariati, Judith Anzures‐Cabrera, Bastian Zinnhardt   +9 more
wiley   +1 more source

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

Nuclear Alpha‐Synuclein: Mechanisms and Implications for Synucleinopathies

Movement Disorders, EarlyView.
Abstract Alpha‐synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson's disease (PD) and related synucleinopathies. Recent advances reveal that aSyn dynamically localizes to neuronal nuclei in both health and disease ...
Tiago Fleming Outeiro, David J. Koss
wiley   +1 more source